IMMUNEONCO-B(01541): The clinical trial results of using IMM0306 in combination with lenalidomide to treat chronic lymphoma stand out.

IMMUNEONCO-B (01541) announcement, the phase Ib/IIa clinical trial of IMM0306 in combination with lenalidomide for the treatment of chronic lymphoma has successfully recruited 27 evaluable patients (25 follicular lymphoma (FL) patients and 2 marginal zone lymphoma (MZL) patients) by October 26, 2024. The efficacy data for recurrent or refractory (R/R) FL patients by October 26, 2024, are shown in the figure below: As of October 26, 2024, the overall response rate (ORR) and complete response rate (CRR) for the 25 evaluable R/R FL patients were 84.0% and 40.0%, respectively, while the overall response rate for the two evaluable R/R MZL patients was 100.0%, indicating a significant efficacy signal. The study is currently actively recruiting and observing. IMM0306, independently developed by the group, is a dual-specificity molecule targeting cluster of differentiation 47 (CD47) and cluster of differentiation 20 (CD20), being the first globally to enter the clinical stage as a CD47 and CD20 dual-targeted dual-specificity molecule. Through enhanced antibody-dependent cell phagocytosis (ADCP) and antibody-dependent cell cytotoxicity (ADCC), IMM0306 can simultaneously bind to CD47 and CD20 expressed on malignant B cells. In comparison to CD47, it has a higher affinity for CD20, thereby improving the therapeutic effect.